Home > Healthcare > Pharmaceuticals > Finished Drug Form > Cancer Biological Therapy Market
Cancer Biological Therapy Market Size
Cancer Biological Therapy Market size was worth more than USD 111.5 billion in 2022 and is expected to record over 7% CAGR from 2023-2032. Rising prevalence of cancer across the globe will accelerate industry expansion.
The growing disease burden and incidences of cancer worldwide will have a significant impact on the cancer biological therapy industry outlook. According to the World Health Organization (WHO), cancer accounted for more than 10 million deaths in 2020. The National Institute of Cancer has further suggested that cancer-related mortality will reach 16.4 million per year by 2040 with 29.5 million new cases annually in the U.S.
Moreover, the fast-paced lifestyles and the higher consumption of highly processed foods, has stirred the substantial increase in alcohol intake resulting in a high prevalence of risk factors, such as obesity and type 2 diabetes. This scenario is therefore emphasizing the need for advanced biological therapies to limit or prevent the growth and spread of tumors.
| Report Attributes | Details |
|---|---|
| Base Year: | 2022 |
| Market Size in 2022: | USD 111.5 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 7% |
| 2032 Value Projection: | USD 227 Billion |
| Historical Data for: | 2018 to 2022 |
| No. of Pages: | 250 |
| Tables, Charts & Figures: | 545 |
| Segments covered: | Product, Route of Administration, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Side effects of anti-cancer drugs may impede product demand
The rising concerns regarding the potential side effects of anti-cancer drugs and biological therapies could restrict industry progress. Some of the common adversities associated with cancer biological therapies include fever, nausea, inflammation, chronic fatigue, disorientation, and depression, among others. While the impact of these drugs varies from patient to patient, they frequently pose a severe threat to the overall health of a patient, necessitating various treatment methods to overcome added complications, result in high hospital expenditure. Nonetheless, rapid technological advancements in cancer therapies could help provide access to safer alternatives.
Cancer Biological Therapy Market Analysis
Cancer biological therapy market valuation from blood cell growth factors (BCGF) is estimated to surpass USD 50 billion by 2032 due to the growing concerns associated with the side effects of cancer treatments. BCGF is increasingly administered in cancer patients to improve their immunity and combat adverse effects such as lower white blood cell count caused by therapies. It helps reduce the risk of infections and potentially boost chemotherapy output by preventing any delay in the procedure. Half of the world’s cancer patients at some point suffer from chemotherapy-induced severe neutropenia, a condition referring to very low WBCs. The growing prevalence of neutropenia as a result of radiation therapy, immunotherapy, stem cell transplant, and cancer itself will also foster the product demand.
Cancer biological therapy market size from the oral segment is projected to depict over 6.5% CAGR between 2023-2032. This is attributed to the surging demand for affordable cancer treatments. Oral treatments have a high preference among patients as well as physicians over injectables as they eliminate several unfavorable side effects, such as soreness at the site of injections, and fever or chills.
Oral drugs are easy to administer and do not require doctor’s assistance. The presence of extensive R&D initiatives and clinical trials pertaining to FDA-approved therapeutics will complement the segment development.
Europe cancer biological therapy market size is slated to reach over USD 55.5 billion by 2032 driven by the rising cases of cancer and the growing geriatric population in the region. According to the European Commission’s Joint Research Center (JRC), the number of individuals diagnosed with cancer is estimated to increase by nearly 18% in 2040 led by the rising geriatric patient pool. Belgium, the Netherlands, Ireland, and Denmark are some of the major hotspots with high cancer prevalence representing lucrative demand for biological therapies. In recent years, Europe has also experienced an upsurge in cancer rates among children.
Cancer Biological Therapy Market Share
Some leading companies in the cancer biological therapy market include
- AbbVie Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Merck
- AstraZeneca
- GlaxoSmithKline plc
- ELI Lilly and Company
- Incyte
- Otsuka
- Pfizer
- Sanofi
- F. Hoffmann-La Roche
- Novartis
- Takeda Pharmaceuticals
- Seattle Genetics
- Spectrum Pharmaceuticals
These companies are focusing on product innovations to achieve competitive lead.
Impact of the COVID-19 pandemic
The COVID-19 crisis negatively influenced the cancer biological therapy market with massive disruptions in the cancer care supply chain. It resulted in a radical drop in sales of cancer drugs due to increasing focus on COVID-19 treatment. With surging hospitalization rates worldwide, several healthcare facilities ceased cancer diagnosis and screening services and delayed cancer-related procedures, negatively affecting cancer therapies. However, the post-pandemic era is expected to offer lucrative opportunities for the manufacturers of cancer biological therapies on account of recovery in non-emergency services across healthcare facilities.
The cancer biological therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Product
- Monoclonal antibodies (MAB)
- Naked MAB
- Conjugated MAB
- Bispecific MAB
- Vaccines
- Preventive vaccines
- Therapeutic vaccines
- Cancer growth blockers
- Tyrosine kinase inhibitors (TKI)
- Proteasome inhibitors (PI)
- mTOR inhibitors
- Blood cell growth factors (BCGF)
- Lenograstim
- Filgrastim
- Cytokines
- Interferons
- Interleukins
By Route of administration
- Oral
- Injectable
The above information is provided for the following regions and countries:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Switzerland
- Netherlands
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
- Indonesia
- Vietnam
- Latin America
- Brazil
- Argentina
- Mexico
- Chile
- Columbia
- Peru
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Egypt
- Iran
Frequently Asked Questions (FAQ) :